OS Therapies Inc. Files 8-K with Financials
Ticker: OSTX · Form: 8-K · Filed: Aug 22, 2024 · CIK: 1795091
| Field | Detail |
|---|---|
| Company | Os Therapies Inc (OSTX) |
| Form Type | 8-K |
| Filed Date | Aug 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
TL;DR
OS Therapies filed an 8-K with financials on 8/22/24.
AI Summary
On August 22, 2024, OS Therapies Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no other specific events detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Grasonville, Maryland.
Why It Matters
This filing indicates that OS Therapies Inc. has submitted its financial statements and exhibits to the SEC, which is a standard requirement for public companies.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for financial statements and exhibits, with no immediate material events disclosed.
Key Numbers
- 001-42195 — SEC File Number (Identifies the company's filing with the SEC.)
- 82-5118368 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- OS Therapies Inc. (company) — Registrant
- August 22, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Grasonville, Maryland (location) — Address of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 22, 2024.
In which state is OS Therapies Inc. incorporated?
OS Therapies Inc. is incorporated in Delaware.
What is the principal executive office address for OS Therapies Inc.?
The principal executive office address is 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638.
Does this filing indicate any other significant events beyond financial statements?
Based on the provided text, the filing primarily concerns 'Other Events' and 'Financial Statements and Exhibits', with no other specific material events detailed.
Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-08-22 16:05:22
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 per share OSTX NYSE American Indi
Filing Documents
- ea0212101-8k_osthera.htm (8-K) — 27KB
- ea021210101ex99-1_osthera.htm (EX-99.1) — 6KB
- 0001213900-24-071832.txt ( ) — 206KB
- ostx-20240822.xsd (EX-101.SCH) — 3KB
- ostx-20240822_lab.xml (EX-101.LAB) — 33KB
- ostx-20240822_pre.xml (EX-101.PRE) — 22KB
- ea0212101-8k_osthera_htm.xml (XML) — 4KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2024 OS THERAPIES INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-42195 82-5118368 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 115 Pullman Crossing Road , Suite 103 Grasonville , Maryland 21638 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: ( 410 ) 297-7793 N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share OSTX NYSE American Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. CURRENT REPORT ON FORM 8-K OS Therapies Incorporated August 22, 2024 Item 8.01. Other Events. On August 22, 2024, OS Therapies Incorporated, an ADC and immunotherapy research and clinical-stage biopharmaceutical company, issued a press release providing a clarification for market participants, specifically brokerage firms, that its common stock is trading on the NYSE American under CUSIP 68764Y207. A copy of the press release is furnished with this report as Exhibit 99.1 and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by OS Therapies Incorporated on August 22, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OS THERAPIES INCORPORATED Dated: August 22, 2024 By: /s/ Paul A. Romness Name: Paul A. Romness, MPH Title: President and Chief Executive Officer 2